Home
News
Breast
Lung
Prostate
Colorectal
Stomach
Bone
Leukemia
Brain
Treatment
Other
Expert Opinions and Interviews
Prevention and Early Detection
Search
Home
News
Breast
Lung
Prostate
Colorectal
Stomach
Bone
Leukemia
Brain
Treatment
Other
Expert Opinions and Interviews
Prevention and Early Detection
Search
Home
Cancer
Cancer
Behavior
Bone
Brain
Breast
Colorectal
Leukemia
Lung
Prostate
Research
Stomach
Research
FDA approves Shorla Oncology’s TEPYLUTE for most cancers therapy
Editor
-
July 6, 2024
Behavior
Predicting Most cancers Conduct Requires Higher Understanding of Tumor Cells
Editor
-
July 6, 2024
From the Journal: BiomicrofluidicsWASHINGTON, June 9, 2020...
Stomach
Nation of Beginning a Think about Abdomen Most cancers
Editor
-
July 6, 2024
By: Kevin McClanahan | November 28, 2023 | 4 min. learn | Share Analysis highlights variations in danger in Latin American and Caribbean nations,...
Breast
PARP inhibition with rucaparib alone adopted by mixture with atezolizumab: Part Ib COUPLET scientific research in superior gynaecological and triple-negative breast cancers
Editor
-
July 6, 2024
Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of mixing PARP inhibitor and immunotherapy in strong tumors. Entrance Oncol. 2020;10:570.PubMed ...
Colorectal
Bowel most cancers is on the rise. Right here’s how immunotherapy medication may assist
Editor
-
July 6, 2024
Vikram Reddy: ...
1
...
658
659
660
...
832
Page 659 of 832
Hot Topics
Reflections on Progress at ASCO 2026
NCI’s Message and High Priorities
NCI’s Message and High Priorities
Load more
